Botanix Pharmaceuticals products
Dermatology Pipeline
Program for Rosacea
BTX1702 is a new product opportunity for the treatment of papulopustular rosacea. Rosacea is a chronic inflammatory skin disease that often begins with a tendency to blush or flush more easily than other people, but can progress into many subtypes, including papulopustular rosacea. Papulopustular rosacea is a highly visible and distressing chronic inflammatory skin disease characterised by intensely inflamed skin and acne-like breakouts across the face, which affects more than 16 million Americans. The BTX1702 program is being expedited based on mechanistic data generated by Botanix that shows synthetic CBD exerts powerful anti-inflammatory and antimicrobial actions in skin – two key activities that are critical for successfully treating rosacea.
Transdermal Gel Formulation for Acne
BTX1503 is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. Acne is a skin condition that manifests in pimples, lumps and cysts and is the leading cause of visits to dermatologists and psychological difficulties in adolescents. It is the most common skin disorder in the US affecting 40-50 million Americans and it is estimated the market will grow to a value of US$5.9bn by 2025. Acne has multiple pathogenetic pathways including sebum overproduction, unwanted sebocyte proliferation, inflammation and bacterial infection. Synthetic CBD has been shown in scientific studies to normalise excessive lipid synthesis of human sebocytes, suppress cell proliferation, and provide an anti-inflammatory effect potentially reduce bacterial infection. In turn, this could help to reduce the occurrence or severity of serious acne.